Fengnian Zhao
A5076379939- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urologic and reproductive health conditions
- Cancer-related molecular mechanisms research
- Higher Education and Teaching Methods
- Radiopharmaceutical Chemistry and Applications
- Power System Optimization and Stability
- Water Systems and Optimization
- Power Systems Fault Detection
- Advanced Malware Detection Techniques
- PARP inhibition in cancer therapy
- Network Security and Intrusion Detection
- Anomaly Detection Techniques and Applications
- Educational Technology and Assessment
- Cancer, Hypoxia, and Metabolism
Sichuan University
2022-2024
West China Hospital of Sichuan University
2022-2024
Beijing Institute of Technology
2007-2022
Tianjin University of Technology
2022
Abstract Ductal adenocarcinoma of the prostate (DA) is relatively rare and highly co‐existent with (AC). This study aimed to investigate distinctive genomic profiles patients DA compared those without. Blood samples were obtained from 144 (36 108 without DA) who diagnosed 2017 2023 at West China Hospital. We performed cell‐free DNA sequencing differences between [DA(+)] [DA(−)], explored potential associations their mutational status prognosis. Pathogenic likely pathogenic alterations...
Abstract Intraductal carcinoma of the prostate (IDC-P) is a lethal cancer subtype that generally coexists with invasive high-grade acinar adenocarcinoma (PAC) but exhibits distinct biological features compared concomitant adenocarcinoma. In this study, we performed whole-exome, RNA, and DNA-methylation sequencing IDC-P, concurrent PAC lesions, adjacent normal tissues isolated from 22 radical prostatectomy specimens. Three evolutionary patterns IDC-P were identified: early divergent, late...
176 Background: The marker of proliferation Ki-67 (KI67) is a well-known biomarker reflecting cell activity and was reported to be associated with the treatment efficacy chemotherapy in different tumors. However, it unknown whether KI67 also has role predicting next-generation hormone therapies, e.g., abiraterone, for patients prostate cancer (PCa). Methods: Clinicopathological data 144 men metastatic PCa who received abiraterone therapy were retrospectively collected. positivity examined by...
<p>Table S6</p>
<p>Table S4</p>
<p>Table S3</p>
<p>Supplementary Methods</p>
<p>Table S4</p>
<p>Table S1-revised</p>
<p>Supplementary Methods</p>
<p>Table S5</p>
<div>Abstract<p>Intraductal carcinoma of the prostate (IDC-P) is a lethal cancer subtype that generally coexists with invasive high-grade acinar adenocarcinoma (PAC) but exhibits distinct biological features compared concomitant adenocarcinoma. In this study, we performed whole-exome, RNA, and DNA-methylation sequencing IDC-P, concurrent PAC lesions, adjacent normal tissues isolated from 22 radical prostatectomy specimens. Three evolutionary patterns IDC-P were identified: early...
<p>Table S7</p>
<div>Abstract<p>Intraductal carcinoma of the prostate (IDC-P) is a lethal cancer subtype that generally coexists with invasive high-grade acinar adenocarcinoma (PAC) but exhibits distinct biological features compared concomitant adenocarcinoma. In this study, we performed whole-exome, RNA, and DNA-methylation sequencing IDC-P, concurrent PAC lesions, adjacent normal tissues isolated from 22 radical prostatectomy specimens. Three evolutionary patterns IDC-P were identified: early...
<p>Supplementary figure 1-15</p>
<p>Table S8</p>
<p>Supplementary figure 1-15</p>
<p>Table S5</p>
<p>Table S1-revised</p>
<p>Table S6</p>
<p>Table S2-revised</p>
<p>Table S8</p>
<p>Table S2-revised</p>
<p>Table S3</p>
<p>Table S7</p>